Sertificate of Registration GMP/LE/2004/002 Sertificate of Registration ISO 9001:2000 Sertificate of Registration ISO 9001:2000
Choose
your language:
English Russian
Choose the firm:
 Registrations
 Our partners
 Contact Us
 Search
 Price
For registered users
login
password
    
featured products
    Glucose 5%
    Cipro-Tech
    Iono-Tech
    Manni-Tech 10%
    Metronidazole 0.5%
    NaCl 0.9%
    Rheopolyglucinum
    Ringer
    Solutio Novocaini 0.25%
    Natrii citrati 4%
    Diprosalic Lotion 30 ml
    Freederm Shampoo Tar 150 ml
    Intron 18 miu 3ml 1 vial
    Triderm Cream 15 g
    Augmentin tab. 375mg N20
    Augmentin inj. 600mg N1
    Dermovate Oint 25g Tube
    Imigran Tab. 50mg N2
    Levitra 5mg 2 tab
    Mylogin Caps 250mg N10
    Mylogin Caps 250mg N20
    Oxybral Caps 30mg N20
    Septrin Paed Susp 100ml N1
    Valtrex tab. 500mg N10
    Vitamax Caps N5
    Zantac Tab. 150mg N20
    Zeffix Tab 100mgx28
    Zinacef Inj 750mg N1
    Zofran Tab 4mg N10
    Zyban 150 mg tabs. X 60
    Wellbutrin SR 150mg 60 tab
    Astmopent Aer 400Ds 0.75mg
    Salbutamol inh
information about product

MANNI-TECH
(Mannitol 10 % Solution for intravenous injection)

The trading (patented) name of a preparation - MANNI-TECH
The international name -
SOLUTION of MANNITOL 10%
ATC-CODE - B05CB01 > STRUCTURE AND THE FORM OF RELEASE
1 litre of a solution contains
Mannitol ........... 100g
Sodium lactate......0,067g
Other components: water for an injection.
250, 400, 500 ml of solution in plastic containers from PVC.


PHARMACOLOGICAL EFFECT
Manni-Tech renders strong diuretic reaction. Effect caused by the increase of osmotic pressure of plasma and move of fluids from tissues (in particular eyeball, brain) in a vascular channel, decrease of water re-absorption. Diuretic effect is characterized by allocation of water, as well as sodium, chlorine, without any essential influence on potassium deduction.

INDICATIONS FOR ADMINISTRATION
Manni-Tech is used to decrease the intracranial pressure and to reduce the hypostasis of brain, oliguria, acute nephros or nephros-hepatic insufficiency with the preserved filtrational ability of kidneys and during other conditions demanding intensity of diuresis. At acute stagnant glaucoma application of Manni-Tech for dehydration is possible. The preparation is prescribed during intensive therapy of convulsive (spasmodic) status.

DOSAGE
Manni-Tech is administered intravenously with calibrated infusion device through slow flow or in drops). For prophylaxis purposes it is administered in a single doze at the rate of 0.5 g/kg of body mass, for medical purposes - 1-1.5 g/kg. The daily doze should not exceed 140-180 g. During operations with artificial blood circulation 20-40 g of preparation is directly entered into the infusion device before the start of perfusion.

SIDE-EFFECTS
Symptoms of water-electrolyte balance disturbances are possible: muscular weakness, spasms, dryness in a mouth, thirst, loss of consciousness; a thrombophlebitis, a skin rash, a tachycardia is possible. During the overdosage of the preparation sypmtoms of dehydration may appear (dyspepsia, hallucination etc.).

CONTRAINDICATIONS
Manni-Tech it is contra-indicated during infringements of secretory function of kidneys, intracranial haemorrhage, (o)edema of lungs, acute haemostasia in a small circle of blood circulation, increased sensitivity towards mannitol.

PREGNANCY AND LACTATION
Contraindications are not revealed.

SPECIAL INDICATIONS
Manni-Tech should be administered cautiously to patients with heavy chronic heart disorders, kidney disorders, hyponatriemia. During the administration of the preparation it is necessary to check arterial pressure, diuresis, electrolyte concentration in the blood serum (potassium, sodium). For the prevention of dehydration, introduction of necessary amounts of fluids to the organism is necessary.

STORAGE CONDITIONS AND SHELF LIFE
To be kept in Órdinary conditions at temperature not higher than +25oC. Expiry date - 2 years.

  Copyright © 2006 PharmaTech